Suppr超能文献

经皮冠状动脉介入治疗后双联抗血小板治疗患者 PRECISE-DAPT 评分与缺血结局的相关性:荟萃分析。

The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis.

机构信息

Division of Cardiology, University of Ottawa Heart Institute, Room H3408, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.

Berkamn Library, University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2022 Aug 11;8(5):511-518. doi: 10.1093/ehjcvp/pvab080.

Abstract

AIMS

The PRECISE-DAPT (Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score identifies patients at high risk of bleeding complications following percutaneous coronary intervention (PCI). International guidelines recommend the PRECISE-DAPT score to identify patients at high risk for bleeding, who may benefit from shortened dual antiplatelet therapy. The association of the PRECISE-DAPT score with ischaemic outcomes remains unclear. We performed a meta-analysis investigating the association between a high PRECISE-DAPT score and ischaemic outcomes.

METHODS AND RESULTS

A comprehensive literature search was conducted on articles published between 11 March 2017 and 5 June 2021. Two reviewers independently screened articles for inclusion using pre-defined criteria. The outcome measures extracted included composite ischaemic events, major bleeding events, and all-cause mortality. A random effects model was applied to obtain combined risk estimates for outcomes. From 12 included studies, there were 39 459 patients with PRECISE-DAPT <25 and 14 761 patients with PRECISE-DAPT ≥25. PRECISE-DAPT score ≥25 was associated with increased risk of composite ischaemic events [odds ratio (OR) 2.16; 95% confidence interval (CI) 1.77-2.65], myocardial infarction (OR 2.06; 95% CI 1.38-3.08), and ischaemic stroke (OR 2.90; 95% CI 1.76-4.78). Patients with a PRECISE-DAPT score ≥25 had increased risk of major bleeding (OR 3.62; 95% CI 2.62-4.99). Patients with a PRECISE-DAPT score ≥25 had higher risk of all-cause mortality (OR 5.83; 95% CI 5.37-6.33).

CONCLUSION

Patients with a PRECISE-DAPT score ≥25 are at increased risk for ischaemic events, bleeding, and all-cause mortality. Prospective evaluation of a PRECISE-DAPT guided approach to antiplatelet therapy is required to demonstrate benefit in this high-risk population.

摘要

目的

PRECISE-DAPT(预测接受支架植入和随后双联抗血小板治疗的患者出血并发症的风险)评分可识别经皮冠状动脉介入治疗(PCI)后出血并发症风险较高的患者。国际指南建议使用 PRECISE-DAPT 评分来识别出血风险较高的患者,这些患者可能受益于双联抗血小板治疗时间的缩短。PRECISE-DAPT 评分与缺血结局的相关性尚不清楚。我们进行了一项荟萃分析,研究了 PRECISE-DAPT 评分较高与缺血结局之间的关系。

方法和结果

对 2017 年 3 月 11 日至 2021 年 6 月 5 日期间发表的文章进行了全面的文献检索。两位审稿人使用预先定义的标准独立筛选文章纳入情况。提取的结局测量包括复合缺血事件、主要出血事件和全因死亡率。采用随机效应模型获得结局的综合风险估计值。从 12 项纳入的研究中,有 39459 例 PRECISE-DAPT<25 的患者和 14761 例 PRECISE-DAPT≥25 的患者。PRECISE-DAPT 评分≥25 与复合缺血事件(比值比[OR] 2.16;95%置信区间[CI] 1.77-2.65)、心肌梗死(OR 2.06;95% CI 1.38-3.08)和缺血性卒中(OR 2.90;95% CI 1.76-4.78)风险增加相关。PRECISE-DAPT 评分≥25 的患者发生主要出血(OR 3.62;95% CI 2.62-4.99)的风险增加。PRECISE-DAPT 评分≥25 的患者全因死亡率(OR 5.83;95% CI 5.37-6.33)的风险更高。

结论

PRECISE-DAPT 评分≥25 的患者发生缺血事件、出血和全因死亡率的风险增加。需要前瞻性评估 PRECISE-DAPT 指导的抗血小板治疗方法,以证明在这一高危人群中的获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验